Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2014

View Archived Issues

Alnylam and Genzyme expand collaboration for RNAi therapeutics

Idenix Pharmaceuticals reports data from phase II all-oral HCV combination regimen

GSK obtains option right to Santaris Pharma's LNA technology

Vaxart's H1N1 influenza vaccine shows promising protective immunity in phase Ib study

Cortice Biosciences begins enrollment in phase II trial of TPI-287 plus Avastin

Cancer Prevention Pharmaceuticals and Tillotts Pharma sign licensing agreement

Seattle Genetics and AbbVie expand antibody-drug conjugate collaboration

Probiodrug and VU University Medical Center to collaborate on Alzheimer's disease biomarker assays

Extended treatment phase of ZS-9 phase III trial in hyperkalemia meets endpoint

Achillion describes clinical development plan for oral HCV treatments

FDA clears BD Diagnostics' BD MAX MRSA XT Assay

GeoVax discloses preliminary topline results from phase I trial of vaccine to control HIV infections

Metabolic suppression-mediated discovery of novel antibacterial inhibitor compounds

Discovery and characterization of an orally potent anti-inflammatory kinase inhibitor

FDA grants QIDP designation to Carbavance

EMA committee recommends suspending use of Protelos/Osseor

Prosensa regains rights to drisapersen from GSK

First patient dosed in phase II trial of BMN-111 in children with achondroplasia

First subjects dosed in phase Il study of NKTR-171

FDA committee recommends approval of Northera NDA for treatment of symptomatic nOH

Complement factor B inhibitors described in recent Novartis patent

Boehringer Ingelheim describes K(Ca) 3.1 channel blockers

Roche reports development of tankyrase inhibitors

U.S. researchers divulge novel bacterial RNA polymerase inhibitors

MAP Pharmaceuticals patent discloses D2/5-HT1D receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...